Aged
C. R. Jack, Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., Roberts, R. O., Rocca, W. A., Boeve, B. F., and Petersen, R. C.,
“An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.”,
Ann Neurol, vol. 71, no. 6, pp. 765-75, 2012.
J. Li, Wang, Y. J., Zhang, M., Xu, Z. Q., Gao, C. Y., Fang, C. Q., Yan, J. C., and Zhou, H. D.,
“Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease.”,
Neurology, vol. 76, no. 17, pp. 1485-91, 2011.
M. Sattlecker, Khondoker, M., Proitsi, P., Williams, S., Soininen, H., Kłoszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Lovestone, S., and Dobson, R. Jb,
“Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease.”,
J Alzheimers Dis, vol. 49, no. 4, pp. 1105-14, 2016.
K. Hoffmann, Sobol, N. A., Frederiksen, K. S., Beyer, N., Vogel, A., Vestergaard, K., Brændgaard, H., Gottrup, H., Lolk, A., Wermuth, L., Jacobsen, S., Laugesen, L. P., Gergelyffy, R. G., Høgh, P., Bjerregaard, E., Andersen, B. B., Siersma, V., Johannsen, P., Cotman, C. W., Waldemar, G., and Hasselbalch, S. G.,
“Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial.”,
J Alzheimers Dis, vol. 50, no. 2, pp. 443-53, 2016.
K. Hoffmann, Sobol, N. A., Frederiksen, K. S., Beyer, N., Vogel, A., Vestergaard, K., Brændgaard, H., Gottrup, H., Lolk, A., Wermuth, L., Jacobsen, S., Laugesen, L. P., Gergelyffy, R. G., Høgh, P., Bjerregaard, E., Andersen, B. B., Siersma, V., Johannsen, P., Cotman, C. W., Waldemar, G., and Hasselbalch, S. G.,
“Moderate-to-High Intensity Physical Exercise in Patients with Alzheimer's Disease: A Randomized Controlled Trial.”,
J Alzheimers Dis, vol. 50, no. 2, pp. 443-53, 2016.
S. Baiardi, Capellari, S., Ladogana, A., Strumia, S., Santangelo, M., Pocchiari, M., and Parchi, P.,
“Revisiting the Heidenhain Variant of Creutzfeldt-Jakob Disease: Evidence for Prion Type Variability Influencing Clinical Course and Laboratory Findings.”,
J Alzheimers Dis, vol. 50, no. 2, pp. 465-76, 2016.
H. Hochstetler, Trzepacz, P. T., Wang, S., Yu, P., Case, M., Henley, D. B., Degenhardt, E., Leoutsakos, J. - M., and Lyketsos, C. G.,
“Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.”,
J Alzheimers Dis, vol. 50, no. 1, pp. 271-82, 2016.
H. Hochstetler, Trzepacz, P. T., Wang, S., Yu, P., Case, M., Henley, D. B., Degenhardt, E., Leoutsakos, J. - M., and Lyketsos, C. G.,
“Empirically Defining Trajectories of Late-Life Cognitive and Functional Decline.”,
J Alzheimers Dis, vol. 50, no. 1, pp. 271-82, 2016.
C. E. Fischer, Qian, W., Schweizer, T. A., Millikin, C. P., Ismail, Z., Smith, E. E., Lix, L. M., Shelton, P., and Munoz, D. G.,
“Lewy Bodies, Vascular Risk Factors, and Subcortical Arteriosclerotic Leukoencephalopathy, but not Alzheimer Pathology, are Associated with Development of Psychosis in Alzheimer's Disease.”,
J Alzheimers Dis, vol. 50, no. 1, pp. 283-95, 2016.
T. Lu, Aron, L., Zullo, J., Pan, Y., Kim, H., Chen, Y., Yang, T. - H., Kim, H. - M., Drake, D., X Liu, S., Bennett, D. A., Colaiácovo, M. P., and Yankner, B. A.,
“REST and stress resistance in ageing and Alzheimer's disease.”,
Nature, vol. 507, no. 7493, pp. 448-54, 2014.
T. Lu, Aron, L., Zullo, J., Pan, Y., Kim, H., Chen, Y., Yang, T. - H., Kim, H. - M., Drake, D., X Liu, S., Bennett, D. A., Colaiácovo, M. P., and Yankner, B. A.,
“REST and stress resistance in ageing and Alzheimer's disease.”,
Nature, vol. 507, no. 7493, pp. 448-54, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R.,
“Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R.,
“Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R.,
“Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R.,
“Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”,
N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
M. Babić Leko, Borovečki, F., Dejanović, N., Hof, P. R., and Šimić, G.,
“Predictive Value of Cerebrospinal Fluid Visinin-Like Protein-1 Levels for Alzheimer's Disease Early Detection and Differential Diagnosis in Patients with Mild Cognitive Impairment.”,
J Alzheimers Dis, vol. 50, no. 3, pp. 765-78, 2016.
F. Piazza, Greenberg, S. M., Savoiardo, M., Gardinetti, M., Chiapparini, L., Raicher, I., Nitrini, R., Sakaguchi, H., Brioschi, M., Billo, G., Colombo, A., Lanzani, F., Piscosquito, G., Carriero, M. Rita, Giaccone, G., Tagliavini, F., Ferrarese, C., and DiFrancesco, J. C.,
“Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”,
Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
O. Bousiges, Cretin, B., Lavaux, T., Philippi, N., Jung, B., Hezard, S., Heitz, C., Demuynck, C., Gabel, A., Martin-Hunyadi, C., and Blanc, F.,
“Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.”,
J Alzheimers Dis, vol. 51, no. 4, pp. 1069-83, 2016.
P. Suppa, Hampel, H., Kepp, T., Lange, C., Spies, L., Fiebach, J. B., Dubois, B., and Buchert, R.,
“Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnestic Mild Cognitive Impairment.”,
J Alzheimers Dis, vol. 51, no. 3, pp. 867-73, 2016.
R. Lizio, Del Percio, C., Marzano, N., Soricelli, A., Yener, G. G., Başar, E., Mundi, C., De Rosa, S., Triggiani, A. Ivano, Ferri, R., Arnaldi, D., Nobili, F. Mariano, Cordone, S., Lopez, S., Carducci, F., Santi, G., Gesualdo, L., Rossini, P. M., Cavedo, E., Mauri, M., Frisoni, G. B., and Babiloni, C.,
“Neurophysiological assessment of Alzheimer's disease individuals by a single electroencephalographic marker.”,
J Alzheimers Dis, vol. 49, no. 1, pp. 159-77, 2016.
R. Lizio, Del Percio, C., Marzano, N., Soricelli, A., Yener, G. G., Başar, E., Mundi, C., De Rosa, S., Triggiani, A. Ivano, Ferri, R., Arnaldi, D., Nobili, F. Mariano, Cordone, S., Lopez, S., Carducci, F., Santi, G., Gesualdo, L., Rossini, P. M., Cavedo, E., Mauri, M., Frisoni, G. B., and Babiloni, C.,
“Neurophysiological assessment of Alzheimer's disease individuals by a single electroencephalographic marker.”,
J Alzheimers Dis, vol. 49, no. 1, pp. 159-77, 2016.
S. E. Leh, Kälin, A. M., Schroeder, C., Park, M. Tae M., M Chakravarty, M., Freund, P., Gietl, A. F., Riese, F., Kollias, S., Hock, C., and Michels, L.,
“Volumetric and shape analysis of the thalamus and striatum in amnestic mild cognitive impairment.”,
J Alzheimers Dis, vol. 49, no. 1, pp. 237-49, 2016.
J. Spiegel, Pirraglia, E., Osorio, R. S., Glodzik, L., Li, Y., Tsui, W., Louis, L. A. Saint, Randall, C., Butler, T., Xu, J., Zinkowski, R. P., Zetterberg, H., Fortea, J., Fossati, S., Wisniewski, T., Davies, P., Blennow, K., and de Leon, M. J.,
“Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.”,
J Alzheimers Dis, vol. 49, no. 1, pp. 93-100, 2016.
J. Spiegel, Pirraglia, E., Osorio, R. S., Glodzik, L., Li, Y., Tsui, W., Louis, L. A. Saint, Randall, C., Butler, T., Xu, J., Zinkowski, R. P., Zetterberg, H., Fortea, J., Fossati, S., Wisniewski, T., Davies, P., Blennow, K., and de Leon, M. J.,
“Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.”,
J Alzheimers Dis, vol. 49, no. 1, pp. 93-100, 2016.
B. Lebwohl, Luchsinger, J. A., Freedberg, D. E., Green, P. H. R., and Ludvigsson, J. F.,
“Risk of dementia in patients with celiac disease: a population-based cohort study.”,
J Alzheimers Dis, vol. 49, no. 1, pp. 179-85, 2016.
